List of Excipients in Branded Drug COSOPT PF

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Akorn	COSOPT PF	dorzolamide hydrochloride and timolol maleate	17478-604	HYDROXYETHYL CELLULOSE
Akorn	COSOPT PF	dorzolamide hydrochloride and timolol maleate	17478-604	MANNITOL
Akorn	COSOPT PF	dorzolamide hydrochloride and timolol maleate	17478-604	SODIUM CITRATE
Akorn	COSOPT PF	dorzolamide hydrochloride and timolol maleate	17478-604	SODIUM HYDROXIDE
Akorn	COSOPT PF	dorzolamide hydrochloride and timolol maleate	17478-604	WATER
Thea Pharma Inc	COSOPT PF	dorzolamide hydrochloride and timolol maleate	82584-604	HYDROXYETHYL CELLULOSE

COSOPT PF Excipient Strategy and Commercial Opportunities

Last updated: August 12, 2026

COSOPT PF is a preservative-free fixed-dose ophthalmic solution containing dorzolamide hydrochloride 2% and timolol maleate 0.5%. Its commercial differentiation comes primarily from preservative-free delivery, unit-dose packaging, tolerability, and adherence rather than molecular exclusivity. The principal excipient opportunity is to reproduce or improve the product’s chemical stability, ocular comfort, drop usability, and packaging economics without introducing a new preservative or materially changing the labeled dosage form.

What is COSOPT PF and which excipients does it contain?

COSOPT PF is an ophthalmic carbonic anhydrase inhibitor and beta blocker combination indicated to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Each milliliter contains dorzolamide hydrochloride equivalent to 20 mg dorzolamide and timolol maleate equivalent to 5 mg timolol.[1]

The labeled inactive ingredients are:

Excipient	Likely formulation function
Hydroxyethyl cellulose	Viscosity modifier, retention aid, drop-control agent
Mannitol	Tonicity adjuster and bulking agent
Sodium citrate dihydrate	Buffer component and pH-control agent
Sodium hydroxide	pH adjustment
Water for injection	Vehicle

The product is supplied in single-use, preservative-free containers. The label instructs patients to discard each container after use and to avoid allowing the container tip to touch the eye or surrounding tissue.[1]

What is the formulation target?

The formulation must maintain:

• Chemical stability of dorzolamide and timolol in the same aqueous vehicle
• Acceptable pH and osmolality
• Low particulate burden
• Sterility through the labeled shelf life
• Adequate viscosity without blurring vision or delaying drainage
• Consistent drop size from a single-use container
• Compatibility with low-cost polymer packaging

The excipient system is relatively simple. That simplicity creates an opportunity for generic manufacturers, but it also leaves limited room for reformulation without generating comparability, stability, or device-performance risk.

How does the COSOPT PF excipient strategy create commercial value?

The core commercial value is the removal of benzalkonium chloride and other conventional ophthalmic preservatives. Chronic exposure to preservatives can contribute to ocular-surface irritation, tear-film instability, and epithelial toxicity, particularly in patients using multiple glaucoma products or receiving long-term therapy.[2]

COSOPT PF therefore targets patients who:

• Have ocular-surface disease or preservative intolerance
• Use multiple topical glaucoma medications
• Require long-term treatment
• Have previously discontinued preserved products because of irritation
• Need a fixed-dose alternative to separate dorzolamide and timolol bottles

The excipient strategy supports this positioning in four ways.

1. Preservative-free differentiation

The absence of a preservative is the principal product attribute. A generic product that uses the same active ingredients but retains a preservative would compete primarily on price and reimbursement. A preservative-free generic can compete directly for the same clinical segment.

2. Viscosity and ocular retention

Hydroxyethyl cellulose can increase residence time and improve drop control. A higher-viscosity formulation may reduce runoff, but excessive viscosity can create blurred vision, poor patient acceptance, or inconsistent dosing. A competitor that optimizes viscosity and container geometry could create a meaningful user-experience advantage without changing the active ingredients.

3. Tonicity and comfort

Mannitol helps control tonicity while avoiding some of the irritation associated with more aggressive ionic adjustment. The formulation must balance comfort against the tonicity contribution of dorzolamide hydrochloride, timolol maleate, and citrate salts.

4. Unit-dose sterility

Single-use packaging allows the product to remain preservative-free after opening. The container system is therefore part of the formulation strategy. Container extractables, leachables, oxygen transmission, seal integrity, fill volume, and drop formation directly affect product quality and commercial cost.

What formulation patents protect COSOPT PF?

COSOPT PF’s publicly recognizable product differentiation is based on the preservative-free formulation and unit-dose presentation. The relevant intellectual-property categories are likely to include:

IP category	Commercial relevance
Fixed-dose dorzolamide/timolol composition	Protects the combination and concentration relationship
Preservative-free ophthalmic formulation	Protects a formulation approach for chronic ocular use
Buffer and viscosity system	May protect specific excipient ranges or stability profiles
Unit-dose container	May cover packaging or delivery configuration
Manufacturing and sterilization	May protect aseptic filling, container processing, or stability control
Method of use	May cover treatment of glaucoma or ocular hypertension
Device and drop-control design	May create separate packaging or delivery protection

A product label is not a complete patent record. FDA approval materials identify the approved formulation and manufacturing controls, but patent scope must be assessed through the FDA Orange Book, USPTO records, international patent databases, and litigation filings.[3][4]

For a generic applicant, the main technical risk is often not the active-ingredient patent. It is the ability to demonstrate pharmaceutical equivalence, bioequivalence where applicable, sterility, container-closure integrity, extractables and leachables control, and stability in a preservative-free package.

What is the Orange Book status of COSOPT PF?

COSOPT PF is an FDA-approved prescription drug marketed as a fixed-dose ophthalmic combination. The relevant regulatory record is the approved new drug application for the preservative-free product, while the active ingredients also have extensive earlier regulatory histories in separate products, including preserved dorzolamide and timolol formulations.[1][5]

Orange Book analysis should distinguish among:

• Patents listed against the COSOPT PF NDA
• Patents listed against earlier dorzolamide or timolol products
• Expired formulation patents
• Unexpired patents covering packaging, methods of use, or manufacturing
• Regulatory exclusivity, which is separate from patent protection

A Paragraph IV certification would be relevant only if an ANDA applicant identifies an unexpired listed patent and asserts that the patent is invalid, unenforceable, or not infringed. A product-specific Orange Book review is required before assigning a definitive launch date or litigation exposure.[3]

When does COSOPT PF lose exclusivity?

The commercial loss of exclusivity depends on the combination of:

1. Listed patent expiry dates
2. Any six-month pediatric extension
3. Regulatory exclusivity periods
4. ANDA approval timing
5. Paragraph IV litigation
6. The ability of a generic applicant to match the preservative-free dosage form

The expiration of a patent covering an active ingredient does not automatically remove all barriers to competition. Formulation, packaging, method-of-use, and manufacturing patents can create narrower but commercially relevant barriers.

How strong is the patent estate for COSOPT PF?

The patent estate is likely moderate rather than structurally dominant.

Factors strengthening the estate

• Preservative-free ophthalmic products can require technically specific excipient and packaging disclosures.
• Unit-dose delivery creates packaging and container-closure claims distinct from active-ingredient claims.
• A formulation that combines dorzolamide and timolol in a stable aqueous vehicle may support narrow composition claims.
• Manufacturing controls for sterile, preservative-free filling can increase development costs for competitors.

Factors weakening the estate

• Dorzolamide and timolol are established small-molecule ophthalmic drugs.
• The active ingredients are not biologics and do not create biosimilar-style interchangeability barriers.
• A competitor may design around specific excipient concentrations.
• A generic applicant can challenge listed patents under Paragraph IV.
• Many formulation concepts, including buffering, tonicity adjustment, and viscosity control, may be difficult to claim broadly without prior-art exposure.

The strongest practical barrier may be product-development execution rather than broad composition patent scope. Preservative-free ophthalmic manufacturing requires validated aseptic processes and reliable unit-dose packaging. Those requirements can delay competitors even when the patent estate is narrow.

What generic entry risks exist for COSOPT PF?

Generic entry risk is material because the product uses known active ingredients and a conventional aqueous ophthalmic dosage form. The highest-probability competitors are companies with existing ophthalmic manufacturing and sterile filling capabilities.

Generic launch scenarios

Scenario	Market effect	Probability drivers
First preservative-free ANDA approval	Rapid price erosion and formulary substitution	Patent clearance, FDA review, manufacturing readiness
Multiple PF generics launch together	Severe price competition	Common approval timing and limited differentiation
Preserved generic launches first	Partial substitution	Payer preference and physician tolerance for preservatives
Device-differentiated PF product	Slower commoditization	Better drop control, lower waste, improved usability
Authorized generic or licensed supply	Controlled price erosion	Originator strategy and manufacturing economics

The first approved preservative-free generic can obtain an important commercial advantage through payer contracting, pharmacy inventory placement, and ophthalmology channel access. A later entrant may need a lower acquisition cost or a device-based benefit to gain share.

What are the Paragraph IV risks?

A Paragraph IV challenge could target:

• The fixed-dose composition
• The preservative-free formulation
• The use of hydroxyethyl cellulose or a comparable viscosity modifier
• Specific pH or buffer ranges
• Unit-dose packaging
• Methods of treating elevated intraocular pressure

The risk profile depends on the exact claims and filing dates. A generic applicant may also use a section viii statement to omit a patented method of use if the remaining approved indications can support labeling. That strategy is more difficult when the patented use overlaps the full product indication.

What excipient alternatives could compete with COSOPT PF?

A competitor does not necessarily need to copy the exact excipient system. Potential design-around approaches include:

Formulation objective	Alternative strategy
Viscosity control	Hypromellose, povidone, or different hydroxyethyl cellulose grade
Tonicity adjustment	Sodium chloride, glycerol, or alternative polyol system
Buffering	Phosphate, borate, citrate, or low-capacity buffer
pH control	Different base-acid adjustment strategy
Ocular residence	Mucoadhesive polymer at a lower concentration
Packaging	Blow-fill-seal polymer ampoules or alternative unit-dose container
Patient convenience	Multi-dose preservative-free valve system

Each alternative carries technical tradeoffs. Phosphate buffers can raise precipitation concerns with certain ophthalmic products. Borate systems may create regulatory and tolerability considerations. Higher polymer levels can impair vision or alter drop size. Multi-dose preservative-free systems improve convenience but introduce valve reliability, microbial ingress, priming, and residual-volume issues.

What manufacturing and IP barriers affect commercial entry?

The main manufacturing barriers are:

• Aseptic filling at ophthalmic scale
• Sterile filtration and bioburden control
• Unit-dose container integrity
• Low extractables and leachables
• Consistent fill volume
• Reliable drop formation
• Long-term stability under temperature excursions
• Control of particulates and visible contamination
• Compatibility between formulation pH and packaging polymer

The container can be as commercially important as the excipient blend. A product with an inexpensive formulation may still have unfavorable economics if the unit-dose package has high resin consumption, low filling throughput, or excessive residual volume.

For a generic company, the preferred strategy is usually to use the simplest excipient system that matches the reference product’s critical quality attributes. A materially different polymer or buffer should be justified through comparative stability, performance, and tolerability data.

How does COSOPT PF compare with preserved dorzolamide/timolol products?

Attribute	COSOPT PF	Preserved dorzolamide/timolol product
Active ingredients	Dorzolamide 2% and timolol 0.5%	Same combination
Preservative	None	Typically contains a preservative
Packaging	Single-use container	Usually multidose bottle
Ocular-surface positioning	Better suited to preservative-sensitive patients	Lower packaging cost
Patient convenience	More frequent opening and disposal	Easier storage and handling
Waste profile	Potentially higher unit-dose waste	Lower packaging waste per dose
Commercial differentiation	Tolerability and preservative avoidance	Price and convenience
Generic development	Requires sterile PF packaging	More established bottle platforms

The clinical and commercial tradeoff is clear. COSOPT PF has a tolerability and ocular-surface advantage, but unit-dose packaging can increase cost, waste, and patient handling burden.

What licensing deals and competitive opportunities exist?

The strongest licensing opportunities are likely to involve technology rather than the underlying active ingredients.

Attractive licensing targets

• Preservative-free multidose dispensing systems
• Low-cost blow-fill-seal unit-dose packaging
• Ophthalmic container technologies with reduced residual volume
• Improved drop-size control
• Polymer systems that preserve ocular comfort at low concentration
• Contract sterile-filling platforms
• Regional commercialization rights for ophthalmic generics

A licensee could combine an established dorzolamide/timolol ANDA platform with a differentiated container system. That approach may create more value than licensing a narrow excipient patent alone.

Regional opportunities

Geographic opportunities are strongest where:

• Preservative-free glaucoma products are reimbursed
• Ophthalmologists treat large populations with chronic ocular-surface disease
• Local sterile ophthalmic manufacturing is limited
• Regulatory pathways recognize reference-product equivalence
• Payers reward reduced treatment intolerance or improved persistence

The U.S. market is likely to be the most patent- and litigation-sensitive. Europe and other regulated markets may place greater emphasis on device usability, preservative exposure, and local substitution rules. Emerging markets may prioritize price, making unit-dose packaging a substantial disadvantage unless local production reduces cost.

What is the revenue exposure from generic competition?

Revenue exposure depends on whether COSOPT PF retains a clinical niche among preservative-sensitive patients. A first generic launch typically produces rapid wholesale price pressure, but the originator can preserve a portion of demand through:

• Brand recognition among ophthalmologists
• Contracts with integrated delivery networks
• Patient support programs
• Supply reliability
• Preservative-free labeling
• Consistent container performance

The greatest erosion risk occurs if multiple PF generics launch simultaneously and payers treat them as interchangeable. The smallest erosion risk occurs when the originator retains strong access contracts and generic entrants have limited sterile ophthalmic capacity.

A manufacturer evaluating the opportunity should model three products separately:

1. A low-cost preservative-free generic matching the reference product
2. A device-differentiated PF product
3. A preserved, lower-cost fixed-dose product

The first option offers the broadest substitutability. The second offers the strongest margin potential. The third has the lowest technical risk but does not directly address the preservative-free segment.

Key Takeaways

• COSOPT PF contains dorzolamide hydrochloride 2% and timolol maleate 0.5% in a preservative-free aqueous formulation.
• Its principal excipients are hydroxyethyl cellulose, mannitol, sodium citrate dihydrate, sodium hydroxide, and water.
• Commercial differentiation comes from preservative avoidance, ocular-surface tolerability, and unit-dose delivery.
• The strongest development opportunity is a low-cost preservative-free generic with optimized drop size, residual volume, and container integrity.
• Excipient design-around options exist, but changes to viscosity, buffer, tonicity, or pH can affect stability and patient comfort.
• The principal entry barriers are sterile manufacturing, packaging performance, stability, and regulatory comparability.
• COSOPT PF is a small-molecule combination product, so biosimilar risk does not apply.
• Paragraph IV risk depends on current Orange Book listings and the scope of any unexpired formulation, packaging, method-of-use, or manufacturing patents.
• Device and packaging licenses may create more commercial value than narrow excipient licenses.
• Generic entry is likely to pressure price, but preservative-sensitive patients may support continued branded demand.

FAQs About COSOPT PF Excipient Strategy

Is COSOPT PF preservative-free?

Yes. COSOPT PF is supplied in single-use containers and does not contain a conventional ophthalmic preservative.[1]

Which excipient controls COSOPT PF viscosity?

Hydroxyethyl cellulose is the principal viscosity-modifying excipient identified in the product labeling.[1]

Can a generic COSOPT PF use different excipients?

Potentially. A generic applicant may use a different excipient system if it satisfies FDA requirements for pharmaceutical equivalence, quality, stability, sterility, performance, and labeling.

Does COSOPT PF face biosimilar competition?

No. COSOPT PF contains small-molecule active ingredients. Competition would proceed through generic-drug pathways rather than biosimilar approval.

Is the COSOPT PF container part of its commercial differentiation?

Yes. Because the product is preservative-free, the single-use container provides microbial protection after manufacture and is central to sterility, dosing consistency, waste, and cost.

References

1. U.S. Food and Drug Administration. (2024). COSOPT PF (dorzolamide hydrochloride and timolol maleate) ophthalmic solution, preservative-free: Prescribing information.
2. U.S. Food and Drug Administration. (2019). Ophthalmic drug products for over-the-counter human use: Guidance for industry.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. United States Patent and Trademark Office. (2024). Patent Public Search.
5. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drug products.